Latrepirdine

Latrepirdine
Clinical data
Trade namesDimebon
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2,3,4,5-tetrahydro-2,8-dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1H-pyrido(4,3-b)indole
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.119.053 Edit this at Wikidata
Chemical and physical data
FormulaC21H25N3
Molar mass319.452 g·mol−1

Latrepirdine (INN, also known as dimebolin and sold as Dimebon) is an antihistamine drug which has been used clinically in Russia since 1983.[1]

Research was conducted in both Russia and western nations into potential applications as a neuroprotective drug to treat Alzheimer's disease and, possibly, as a nootropic, as well.[2] After a major phase III clinical trial for Alzheimer's disease (AD) treatment failed to show any benefit, three other AD trials continued.[3] Major industry-based development in this indication essentially stopped after another Phase III trial suffered the same fate in 2012.[4] Latrepirdine failed in the phase III trial for Huntington disease.[5]

  1. ^ Matveeva IA (July–August 1983). "[Action of dimebon on histamine receptors]". Farmakologiia I Toksikologiia (in Russian). 46 (4): 27–29. PMID 6225678.
  2. ^ Shevtsova EF, Kireeva EG, Bachurin SO (2005). "[Mitochondria as the target for neuroprotectors]". Vestnik Rossiiskoi Akademii Meditsinskikh Nauk (in Russian) (9): 13–17. PMID 16250325.
  3. ^ Novel Alzheimer's Drug Flops, MedPage Today, March 03, 2010
  4. ^ Sweetlove M (2012). "Phase III CONCERT Trial of Latrepirdine. Negative results". Pharmaceutical Medicine. 26 (2): 113–115. doi:10.1007/BF03256900. S2CID 699473.
  5. ^ Cite error: The named reference HD was invoked but never defined (see the help page).